245 related articles for article (PubMed ID: 19658346)
1. [Hormonal therapy with aromatase inhibitor in advanced breast cancer].
Vrbanec D; Belev B; Pavlinić-Diminić V; Pezerović D; Dusper B; Plestina S; Unusić J
Lijec Vjesn; 1998; 120(10-11):315-8. PubMed ID: 19658346
[TBL] [Abstract][Full Text] [Related]
2. Survival with aromatase inhibitors and inactivators versus standard hormonal therapy in advanced breast cancer: meta-analysis.
Mauri D; Pavlidis N; Polyzos NP; Ioannidis JP
J Natl Cancer Inst; 2006 Sep; 98(18):1285-91. PubMed ID: 16985247
[TBL] [Abstract][Full Text] [Related]
3. Switching to an aromatase inhibitor provides mortality benefit in early breast carcinoma: pooled analysis of 2 consecutive trials.
Boccardo F; Rubagotti A; Aldrighetti D; Buzzi F; Cruciani G; Farris A; Mustacchi G; Porpiglia M; Schieppati G; Sismondi P
Cancer; 2007 Mar; 109(6):1060-7. PubMed ID: 17295293
[TBL] [Abstract][Full Text] [Related]
4. Serum TIMP-1 and response to the aromatase inhibitor letrozole versus tamoxifen in metastatic breast cancer.
Lipton A; Leitzel K; Chaudri-Ross HA; Evans DB; Ali SM; Demers L; Hamer P; Brown-Shimer S; Pierce K; Gaur V; Carney W
J Clin Oncol; 2008 Jun; 26(16):2653-8. PubMed ID: 18443351
[TBL] [Abstract][Full Text] [Related]
5. Aromatase inhibitors: future directions.
Osborne CK; Schiff R
J Steroid Biochem Mol Biol; 2005 May; 95(1-5):183-7. PubMed ID: 16019204
[TBL] [Abstract][Full Text] [Related]
6. Prospects of neoadjuvant aromatase inhibitor therapy in breast cancer.
Dixon JM
Expert Rev Anticancer Ther; 2008 Mar; 8(3):453-63. PubMed ID: 18366292
[TBL] [Abstract][Full Text] [Related]
7. Current status of hormonal treatments for metastatic breast cancer in postmenopausal women.
Wasaff B
Oncol Nurs Forum; 1997 Oct; 24(9):1515-20; quiz 1521-2. PubMed ID: 9348592
[TBL] [Abstract][Full Text] [Related]
8. Adequacy of estrogen suppression with aminoglutethimide and hydrocortisone as treatment of human breast cancer: correlation of hormonal data with clinical responses.
Santen RJ; Worgul TJ; Samojlik E; Boucher AE; Lipton A; Harvey H
Cancer Res; 1982 Aug; 42(8 Suppl):3397s-3401s. PubMed ID: 7083205
[TBL] [Abstract][Full Text] [Related]
9. [Aromatase inhibitors in advanced breast cancer].
Spinelli GP; Tomao F; Miele E; Pasciuti G; Russillo M; Tomao S
Recenti Prog Med; 2008 Jan; 99(1):34-8. PubMed ID: 18389871
[TBL] [Abstract][Full Text] [Related]
10. [2d and 3d line hormonal therapy in postmenopausal metastatic breast tumor. Comparison of medroxyprogesterone acetate and aminoglutethimide in tamoxifen-resistant patients].
Garcia-Giralt E; Omodei Zorini C; Ferri L; Ayme Y; Carton M; Daban A; Delozier T; Fargeot P; Fumoleau P; Gorins A
Clin Ter; 1994 Aug; 145(8):113-21. PubMed ID: 7955956
[TBL] [Abstract][Full Text] [Related]
11. Aminoglutethimide as second line endocrine therapy in advanced breast cancer.
Brufman G; Biran S
Anticancer Res; 1986; 6(5):1065-8. PubMed ID: 3800315
[TBL] [Abstract][Full Text] [Related]
12. High dehydroepiandrosterone-sulfate predicts breast cancer progression during new aromatase inhibitor therapy and stimulates breast cancer cell growth in tissue culture: a renewed role for adrenalectomy.
Morris KT; Toth-Fejel S; Schmidt J; Fletcher WS; Pommier RF
Surgery; 2001 Dec; 130(6):947-53. PubMed ID: 11742322
[TBL] [Abstract][Full Text] [Related]
13. Hormonal therapy for advanced breast cancer.
Rugo HS
Hematol Oncol Clin North Am; 2007 Apr; 21(2):273-91. PubMed ID: 17512449
[TBL] [Abstract][Full Text] [Related]
14. The estrogen suppression after sequential treatment with formestane in advanced breast cancer patients.
Zilembo N; Bajetta E; Bichisao E; Martinetti A; La Torre I; Bidoli P; Longarini R; Portale T; Seregni E; Bombardieri E
Biomed Pharmacother; 2004 May; 58(4):255-9. PubMed ID: 15183852
[TBL] [Abstract][Full Text] [Related]
15. Aminoglutethimide as second line therapy in advanced breast cancer.
Elomaa I; Blomqvist C; Rissanen P
Breast Cancer Res Treat; 1986; 7 Suppl():S51-4. PubMed ID: 3017481
[TBL] [Abstract][Full Text] [Related]
16. [A case of aromatase inhibitor-tolerant metastatic breast cancer revealing complete remission with high-dose toremifene therapy].
Kurozumi S; Takeo T; Ikeda F; Horiguchi J; Takeyoshi I; Ito H
Gan To Kagaku Ryoho; 2011 Jan; 38(1):93-6. PubMed ID: 21368465
[TBL] [Abstract][Full Text] [Related]
17. Adjuvant endocrine therapy for perimenopausal women with early breast cancer.
Ortmann O; Cufer T; Dixon JM; Maass N; Marchetti P; Pagani O; Pronzato P; Semiglazov V; Spano JP; Vrdoljak E; Wildiers H
Breast; 2009 Feb; 18(1):2-7. PubMed ID: 19036588
[TBL] [Abstract][Full Text] [Related]
18. Tamoxifen and aromatase inhibitors differentially affect vascular endothelial growth factor and endostatin levels in women with breast cancer.
Holmes CE; Huang JC; Pace TR; Howard AB; Muss HB
Clin Cancer Res; 2008 May; 14(10):3070-6. PubMed ID: 18483373
[TBL] [Abstract][Full Text] [Related]
19. Endocrine therapy for breast cancer: an overview.
Cheung KL
Breast; 2007 Aug; 16(4):327-43. PubMed ID: 17499991
[TBL] [Abstract][Full Text] [Related]
20. Randomized trial of aminoglutethimide versus tamoxifen in metastatic breast cancer.
Lipton A; Harvey HA; Santen RJ; Boucher A; White D; Bernath A; Dixon R; Richards G; Shafik A
Cancer Res; 1982 Aug; 42(8 Suppl):3434s-3436s. PubMed ID: 7044526
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
